Abstract | BACKGROUND: METHODS: RESULTS: Clinician- and patient-rated scores for nasal obstruction (including obstruction on awakening), rhinorrhea, sneezing, and nasal itching were reduced by the first visit at 7 days after initiation of active treatment and remained lower than those of patients receiving placebo throughout the 6-month treatment period. Nasal eosinophilia was reduced in significantly more patients receiving active treatment. The incidence of adverse events was similar in all four treatment groups except for blood in nasal mucus, which was reported by significantly more patients in the two twice-daily active treatment groups compared with the placebo group. There was no evidence of systemic effects of fluticasone propionate. There were no significant differences between fluticasone propionate given once or twice daily or beclomethasone dipropionate given twice daily for any efficacy or safety evaluation. CONCLUSIONS:
|
Authors | A van As, E A Bronsky, R J Dockhorn, J Grossman, W Lumry, E O Meltzer, J M Seltzer, P R Rogenes |
Journal | The Journal of allergy and clinical immunology
(J Allergy Clin Immunol)
Vol. 91
Issue 6
Pg. 1146-54
(Jun 1993)
ISSN: 0091-6749 [Print] United States |
PMID | 8509578
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androstadienes
- Anti-Inflammatory Agents
- Glucocorticoids
- Fluticasone
- Beclomethasone
|
Topics |
- Administration, Topical
- Adolescent
- Adult
- Aged
- Androstadienes
(administration & dosage, adverse effects, therapeutic use)
- Anti-Inflammatory Agents
(administration & dosage, adverse effects, therapeutic use)
- Beclomethasone
(administration & dosage, adverse effects, therapeutic use)
- Child
- Double-Blind Method
- Drug Administration Schedule
- Female
- Fluticasone
- Glucocorticoids
- Humans
- Male
- Middle Aged
- Rhinitis, Allergic, Perennial
(drug therapy)
|